by Sophie Burkholder
Michael Mitchell, Ph.D., Skirkanich Assistant Professor of Innovation in the Department of Bioengineering at the University of Pennsylvania, was elected Chair of the Drug Delivery Special Interest Group for the Society for Biomaterials at the 2019 Annual Meeting in Seattle, Washington. According to the Society for Biomaterials website:
The Drug Delivery Special Interest Group will deal with the science and technology of controlled release of active agents from delivery systems. Controlled drug release is achieved by the use of diffusion, chemical reactions, dissolutions or osmosis, used either singly or in combination. While the vast majority of such delivery devices are based on polymers, controlled release can also be achieved by the use of mechanical pumps. In a broader sense, controlled release also involves control over the site of action of the active agent, using the active agent using pro-drugs, targetable water soluble polymers or various microparticulate systems. Relevant aspects of toxicology, bioavailability, pharmacokinetics, and biocompatibility are also included.
The Society for Biomaterials is an interdisciplinary organization comprised of academic, industry, health care, and governmental professionals dedicated to promoting advancements in all aspects of biomaterial science and engineering, education, and professional standards to enhance human health and quality of life. The Society for Biomaterials was established in 1974, and is the oldest scientific organization in the field of biomaterials.
Mitchell joined the Department of Bioengineering at Penn in 2018 as Skirkanich Assistant Professor of Innovation. Previously, he was an NIH Ruth L. Kirschstein Postdoctoral Fellow with Institute Professor Robert Langer at the Koch Institute for Integrative Cancer Research at MIT. His research interests include biomaterials, drug delivery, and cellular and molecular bioengineering for applications in cancer research, immunotherapy, and gene therapy. Since joining Penn in 2018, Mitchell has received the NIH Director’s New Innovator Award, the Burroughs Wellcome Fund Career Award at the Scientific Interface, a Rising Star Award from the Biomedical Engineering Society, and the T. Nagai Award from the Controlled Release Society.
Mitchell’s new role as the Chair of the SFB’s Drug Delivery Special Interest Group will allow him to lead conversations across academia on the future of drug delivery as it relates to biomaterials. With his fellow officers, Mitchell will help spread knowledge about the field of controlled drug release by hosting research forums, helping to publish news and activities of the SFB in Biomaterials Forum, and foster connections and mentorship among members of his and other Special Interest Groups. We can’t wait to see where Mitchell’s leadership will help take the community of research on areas like toxicology, pharmacokinetics, and biocompatibility next!